Ahead Of The Curve: Amarin To Release Better Than Expected Combo/Statin Data [View instapost]
Agree amrn bag holder, This is the best drug with best safety profile and look where the stock price is trading now. I guess, management's initial decisions are responsible for this to some extent. They started making big noise regarding buyout way early when they should have launched their drug right after approval with focus on hiring sales rep. They should have made planning way before approval instead of launching the drug 6 months after fda approval. This is ridiculous where the stock is trading now.
Bull, Bear, Or Indifferent: Profiting From Amarin's Latest [View article]
Andrew, I'm hugely invested in amrn with options expiring Jan 15 strike $10. I think we might not see nce and nobody knows when that will happen. Yes, combo results will be a good boost for the lagging price in the stock. This price is all related to nce mess up that should have been resolved by this point but nobody knows what's going on at FDA.
Amarin Hit Hard On Summer Street Commentary, Acquisition Possible After Omthera Buyout [View article]
Why you keep on referring about the buyout or the target price of amrn from $14 to $20. Do you even know the market potential for anchor indication. A drug not approved yet and bought out for $14 with only indication for treating TG above 500 and how can you be so conservative with amrn. It's a normal slow process initially for new drugs approved, roughly 5 to 8 months before sales really pick up. I have the hands on experience with almost every new drug approved. Just wait another 3 to 4 months for sales to pick up quickly and let anchor indication be approved by fda and then you will realize the potential of vascepa. I'm not concerned about vascepa at all as I see new rx's numbers going up in our local pharmacy on monthly basis.
Microsoft And Judge Jackson Gives Vringo More Firepower? [View article]
Kevin, When can we hear more about the patents that Vringo obtained from MSFT. I agree, the stock price will move based on that information alone since investors will be able to digest that information regarding the value of those patents. Thanks
The Future Of Omega-3 Based Lipid Management: All Eyes On Amarin [View article]
People we should listen to more adam since he is a biotech analyst and an experts, pun inteded (lol). Steve, it will be matter of time when vascepa will regain majority of market share and we will see increase in rx count in coming months. Thanks for the well written article. take care
Well, Steve It was a wonderful opportunity to add more to 2015 jan 10 options. golden opportunity and amarin will succeed in coming months. Appreciate your hard work on amarin. thanks
Recent Questcor Short Squeeze Confirmed, Continuation Possible [View article]
Brian, Agree, this will the last time the stock will be trading in low 30's due to market volatility and profit taking but come 2nd qtr. earnings, the stock will shoot and shorts will be squeezed in a corner where there will be turning back.
Can Judge Jackson Impose An Injunction Against Google's Unconfirmed Workaround? [View article]
Thanks for providing a more clarity on the final rejection of patents by the patent office. Let's see how it plays in coming days, I guess at this point it all depends how Judge Jackson is going to play on this case. Nothing matters more than Judge Jackson's decision. I believe he already delayed this case to this extent and hope it is not delayed further. Nobody knows the vicious forces that are trying to make VRNG fail. Good Luck to everybody.
Italian OTC Fish Oil Study Has No Bearing On Vascepa Outcomes [View instapost]
Come on Steve, Adam deserves some respect here in regards to his coverage about biotech stocks. No insult for this legendary analyst with his background in science. He has a BS degree in garbage science so please he deserves some respect for providing excellent coverage in regards to amarin and other stocks.
Ahead Of The Curve: Amarin To Release Better Than Expected Combo/Statin Data [View instapost]
This is the best drug with best safety profile and look where the stock price is trading now. I guess, management's initial decisions are responsible for this to some extent. They started making big noise regarding buyout way early when they should have launched their drug right after approval with focus on hiring sales rep. They should have made planning way before approval instead of launching the drug 6 months after fda approval. This is ridiculous where the stock is trading now.
Ahead Of The Curve: Amarin To Release Better Than Expected Combo/Statin Data [View instapost]
Why delay in combo result, it should have been released by this point?
Ahead Of The Curve: Amarin To Release Better Than Expected Combo/Statin Data [View instapost]
When do we expect data to be release, in june or july?
Bull, Bear, Or Indifferent: Profiting From Amarin's Latest [View article]
Amarin Hit Hard On Summer Street Commentary, Acquisition Possible After Omthera Buyout [View article]
Microsoft And Judge Jackson Gives Vringo More Firepower? [View article]
When can we hear more about the patents that Vringo obtained from MSFT. I agree, the stock price will move based on that information alone since investors will be able to digest that information regarding the value of those patents.
Thanks
5 Stocks To Watch For Gains Next Week [View article]
The Future Of Omega-3 Based Lipid Management: All Eyes On Amarin [View article]
take care
Kudos To Adam Feurstein, For Once... [View instapost]
It was a wonderful opportunity to add more to 2015 jan 10 options.
golden opportunity and amarin will succeed in coming months. Appreciate your hard work on amarin.
thanks
Recent Questcor Short Squeeze Confirmed, Continuation Possible [View article]
Can Judge Jackson Impose An Injunction Against Google's Unconfirmed Workaround? [View article]
How Will Judge Jackson Handle Google's Confirmed Workaround? [View article]
Italian OTC Fish Oil Study Has No Bearing On Vascepa Outcomes [View instapost]
Google Cannot Penetrate Vringo's 7th Amendment Armor [View article]
Stop Gambling On Patent Lawsuits [View article]